课题基金 / 基金详情

Enhanced sensitivity HP-gas MRI/PET Dual Modality Imaging for Alzheimer's disease detection.

Enhanced sensitivity HP-gas MRI/PET Dual Modality Imaging for Alzheimer's disease detection.
用于阿尔茨海默病检测的增强灵敏度 HP 气体 MRI/PET 双模态成像。
批准号:
566561-2021
负责人:
Reznik, AllaAV
金额:
$16.76万
依托单位:
依托单位国家:
加拿大
项目类别:
Alliance Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
已结题
起止时间:
2022-01-01 至 2023-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Medical imaging technologies play a crucial role in early diagnosis and management of a variety of diseases, aswell as in clinical research and drug development. Continued developments of medical imaging systems havevastly improved our ability to visualize body tissues and processes, enabling more accurate detection ofmedical conditions. However, recent trends for personalized medicine call for new approaches in precisiondiagnostics with organ-specific imaging tools customized for particular organs or diseases. Dual-modalityimaging is an integral part of this approach as it offers complimentary visual and quantitative information thatis based on aligned morphological and functional data and therefore provides the highest efficacy anddiagnostic capability.One of the biggest areas of impact is Alzheimer's Disease (AD) where precision imaging is required foraccurate identification of a combination of specific AD biomarkers. This holds a promise to predict the futuredevelopment of dementia in patients at risk and to enable the diagnosis of Alzheimer's pathology at the earlystages when available treatments are maximally effective. It is also of a high importance to stratify cohort ofpatients for clinical trials with AD modifying therapies and for clinical neuroscience research.The overarching goal of this proposal is to develop an imaging system that will combine brain-dedicatedPositron Emission Tomography (PET) with Magnetic Resonance Imaging (MRI) for precisionbiomarker-guided medicine in AD. The proposed PET/MRI system will have some unique advantages toimprove early and differential diagnosis of AD through combining the metabolic and molecular informationfrom PET and structural, functional information from MRI. The commercialization and clinical use of theproposed PET/MRI technology will overcome "one-size-fits-all" approach for AD detection, intervention andprevention, and will advance the field of AD management beyond the current standard of care in Canada, andglobally.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
TCF7L2突变介导SMAD7信号轴抑制KRAS突变型结直肠癌转移及耐药的分子机制研究
  • 批准号:
    32000555
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    徐亮
  • 依托单位:
从胰岛素信号传导通路探讨宫内发育迟缓致胰岛素敏感性降低的分子机制
  • 批准号:
    30901614
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2009
  • 负责人:
    邢燕
  • 依托单位: